United States Securities and Exchange Commission · EDGAR Accession 0002020584-26-000001

Form C-AR

Annual Report — Regulation Crowdfunding
Issuer CIK 2020584
Period 2025-12-31

Siren Biotechnology, Inc

CorporationDEIncorporated 2020San Francisco, CAsirenbiotechnology.com
B

Financial Condition

two fiscal years, as filed
Pre-revenueBurn increasingDebt / assets 3%5 employees
Line itemMost recent FYPrior FYΔ
Revenue00
Cost of goods sold00
Net income(10,884,000)(4,666,672)▼ burn
Total assets12,018,00017,539,808▼ 31%
Cash & equivalents11,934,00017,448,263▼ 32%
Accounts receivable00
Short-term debt377,000784,882▼ 52%
Long-term debt00
Taxes paid00

Figures in USD as reported by the issuer.